Literature DB >> 792339

Activation of human B lymphocytes. II. Cellular interactions in the PFC response of human tonsillar and peripheral blood B lymphocytes to polyclonal activation by pokeweed mitogen.

A S Fauci, K R Pratt, G Whalen.   

Abstract

A recently described system for the induction and assay of plaque-forming cells (PFC) following polyclonal stimulation of human B lymphocytes was employed to delineate the cellular requirements for pokeweed mitogen (PWM)-induced activation of human tonsillar and peripheral blood B lymphocytes. It was found that the process was not dependent on the presence of monocytes, but was dependent on the presence of T cells. T cell depleted suspensions of tonsillar as well as peripheral blood lymphocytes had markedly diminished if not absent PFC responses following PWM stimulation. The PFC responses of T cell depleted cultures of tonsil and blood could be reconstituted by adding back T cells. T cell supernatants could also reconstitute the PFC response of T cell depleted tonsillar lymphocytes but not of T cell depleted blood lymphocytes, thus suggesting a more stringent T cell requirement of the PWM-induced PFC response of blood lymphocytes. Enrichment for T cells on the other hand enhanced PFC responses in both organs, particularly in those cultures which had low responses in unfractionated suspensions demonstrating the requirement of optimal T cell help for maximal PFC responses. This study demonstrates the feasibility and effectiveness of this PFC system in elucidating some of the complex regulatory processes associated with the activation of human B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 792339

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Differential sensitivity of lymphocyte subpopulations to suppression by low density lipoprotein inhibitor, an immunoregulatory human serum low density lipoprotein.

Authors:  L K Curtiss; T S Edgington
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

2.  Human IgE biosynthesis by tonsils.

Authors:  K Ohta; A Ishii; T Horiuchi; T Miyamoto; C H Kirkpatrick
Journal:  Clin Rev Allergy       Date:  1989

3.  Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies.

Authors:  J T Golay; D H Crawford
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

4.  The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes.

Authors:  B F Haynes; A S Fauci
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

5.  T-lymphocyte dependency of B-lymphocyte blastogenic response to phytomitogens.

Authors:  T Han; B Dadey
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

6.  Cell-mediated immune response to bacterial products in human tonsils and peripheral blood lymphocytes.

Authors:  M M Drucker; Y Agatsuma; I Drucker; E Neter; J Bernstein; P L Ogra
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets.

Authors:  B F Haynes; G S Eisenbarth; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

8.  Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis.

Authors:  P Katz; A S Fauci
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

9.  Analysis of in vitro polyclonal B cell differentiation responses to bacterial peptidoglycan and pokeweed mitogen in rheumatoid arthritis.

Authors:  I Pardo; C Carafa; R Dziarski; A I Levinson
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

10.  Expression of cell surface markers after human B lymphocyte activation.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.